Web Analytics

3 Latest Announced Rounds

$2,265.93M Raised in 95 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Sudo Biosciences

start up
United States - Menlo Park, California
  • 21/12/2023
  • Series B
  • $116,000,000

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.


Related People

Scott ByrdFounder

Scott Byrd United States - Zionsville, Indiana

Professional experience includes cross-functional roles across multiple therapeutic areas in the pharmaceutical industry: marketing, corporate strategy, commercial strategy, clinical development strategy, sales, hospital product sales and marketing, corporate finance, engineering, and manufacturing.

Specialties: Pharmaceutical marketing, pharmaceutical sales, hospital marketing, hospital sales, marketing strategy, coporate strategy, finance, pharmaceutical pricing reimbursement and access, pharmaceutical launch experience, cardiovascular, critical care, infectious disease.